Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database (March 2019–March 2020), we analysed esketamine-related adverse events (AEs) to detect and characterize relevant safety signals. Methods: We used the consolidated case/non-case approach to estimate the reporting odds ratio (ROR) and information component (IC) with relevant confidence intervals (95% CI) for esketamine-related AEs with ≥4 counts. Comparisons between serious and non-serious AEs were performed using non-parametric tests. Results: The FAERS database contained 962 cases of esketamine-related AEs, with signals detected for several AEs, such as dissociation (ROR = 1,612.64, 95% CI = 1,354.63, 1,919.79; IC = 8.19, 95% CI = 7.96, 8.35), sedation (ROR = 238.46, 95% CI = 202.98, 280.15; IC = 7, 95% CI = 6.75, 7.18), feeling drunk (ROR = 96.17, 95% CI = 61.42, 150.57; IC = 4.84, 95% CI = 4.09, 5.36), suicidal ideation (ROR = 24.03, 95% CI = 18.72, 30.84; IC = 4.31, 95% CI = 3.9, 4.61), and completed suicide (ROR = 5.75, 95% CI = 3.18, 10.41; IC = 2.25, 95% CI = 1.23, 2.94). Signals for suicidal and self-injurious ideation, but not suicide attempt and completed suicide, remained when comparing esketamine to venlafaxine. Females and patients receiving antidepressant polypharmacy, co-medication with mood stabilizers, antipsychotics, benzodiazepines, or somatic medications were more likely to suffer from serious versus non-serious AEs (χ 2 = 125.29, p < 0.001, χ 2 = 9.08, p = 0.003, χ 2 = 8.14, p = 0.004, χ 2 = 19.48, p < 0.001, χ 2 = 25.62, p < 0.001, and χ 2 = 16.79, p < 0.001, respectively). Conclusions: Esketamine may carry a clear potential for serious AEs, which deserves urgent clarification by means of further prospective studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, a pharmacovigilance analysis found some specific patients reported more serious adverse events (women, obese people, people with comorbidities and with poly-pharmacy) [25].”
In the citing paper
“Possible safety issues have indeed been described in post-marketing studies [25, 52].”
In the citing paper
“As detailed above, esketamine-associated adverse events across trials have raised significant concern, particularly with regard to inducing suicidality [115].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [115]
Citations
Cites
Evans, S. J. W., Waller, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,802
A Bayesian neural network method for adverse drug reaction signal generation
Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., & De Freitas, R. M. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050466 · Cited by 1,476
Ford, I., & Norrie, J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510059 · Cited by 1,405
van Puijenbroek, E. P., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R., & Egberts, A. C. G. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.668 · Cited by 1,372
Explanatory and Pragmatic Attitudes in Therapeutical Trials
Schwartz, D., & Lellouch, J. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.01.012 · Cited by 1,252
Explanatory and pragmatic attitudes in therapeutical trials
Schwartz, D., & Lellouch, J. (1967) · Journal of Chronic Diseases · doi:10.1016/0021-9681(67)90041-0 · Cited by 1,185
The reporting odds ratio and its advantages over the proportional reporting ratio
Rothman, K. J., Lanes, S., & Sacks, S. T. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1001 · Cited by 1,111
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6048 · Cited by 1,048
Quantitative signal detection using spontaneous ADR reporting
Bate, A., & Evans, S. J. W. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1742 · Cited by 912
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class
Kim, J., Farchione, T., Potter, A., Chen, Q., & Temple, R. (2019) · New England Journal of Medicine · doi:10.1056/nejmp1903305 · Cited by 333
Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308
Zarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
Pariente, A., Gregoire, F., Fourrier-Reglat, A., Haramburu, F., & Moore, N. (2007) · Drug Safety · doi:10.2165/00002018-200730100-00007 · Cited by 268
Perspectives on the Use of Data Mining in Pharmacovigilance
Almenoff, J., Tonning, J. M., Gould, A. L., Szarfman, A., Hauben, M., Ouellet-Hellstrom, R., Ball, R., Hornbuckle, K., Walsh, L., Yee, C., et al. (2005) · Drug Safety · doi:10.2165/00002018-200528110-00002 · Cited by 250
Hoffman, K. B., Dimbil, M., Erdman, C. B., Tatonetti, N. P., & Overstreet, B. M. (2014) · Drug Safety · doi:10.1007/s40264-014-0150-2 · Cited by 211
Beck, K., Hindley, G., Borgan, F., Ginestet, C., McCutcheon, R., Brugger, S., Driesen, N., Ranganathan, M., D’Souza, D. C., Taylor, M., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.4693 · Cited by 183
Ketamine and other glutamate receptor modulators for depression in adults
Caddy, C., Amit, B. H., McCloud, T. L., Rendell, J. M., Furukawa, T. A., McShane, R., Hawton, K., & Cipriani, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub2 · Cited by 174
de Leon, J., Ruan, C.-J., Schoretsanitis, G., & De las Cuevas, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507638 · Cited by 164
Self-citationDecision support methods for the detection of adverse events in post-marketing data
Hauben, M., & Bate, A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.012 · Cited by 163
Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval
Turner, E. H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30394-3 · Cited by 156
Raschi, E., Poluzzi, E., Salvo, F., Pariente, A., De Ponti, F., Marchesini, G., & Moretti, U. (2018) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.02.014 · Cited by 119
Self-citationUS Food and Drug Administration approval of esketamine and brexanolone
Cristea, I. A., & Naudet, F. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30292-5 · Cited by 98
A Word to the Wise About Intranasal Esketamine
Schatzberg, A. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19040423 · Cited by 96
Rational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Chavant, F., Favrelière, S., Lafay‐Chebassier, C., Plazanet, C., & Pérault‐Pochat, M. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04009.x · Cited by 92
Gender differences in subjective discontinuation symptoms associated with ketamine use
Chen, W.-Y., Huang, M.-C., & Lin, S.-K. (2014) · Substance Abuse Treatment, Prevention, and Policy · doi:10.1186/1747-597x-9-39 · Cited by 87
Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant
Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0081-2 · Cited by 80
Esketamine: a glimmer of hope in treatment-resistant depression
Kaur, U., Pathak, B. K., Singh, A., & Chakrabarti, S. S. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01084-z · Cited by 74
Doherty, T., Wajs, E., Melkote, R., Miller, J., Singh, J. B., & Weber, M. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00699-4 · Cited by 68
Gatti, M., Antonazzo, I. C., Diemberger, I., De Ponti, F., & Raschi, E. (2021) · European Journal of Preventive Cardiology · doi:10.1177/2047487320915663 · Cited by 68
Self-citationVickers‐Smith, R., Sun, J., Charnigo, R. J., Lofwall, M. R., WALSH, S. L., & Havens, J. R. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107709 · Cited by 56
Esketamine for treatment resistant depression: a trick of smoke and mirrors?
Gastaldon, C., Papola, D., Ostuzzi, G., & Barbui, C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796019000751 · Cited by 54
Self-citationAre we repeating mistakes of the past? A review of the evidence for esketamine
Horowitz, M. A., & Moncrieff, J. (2021) · The British Journal of Psychiatry · doi:10.1192/bjp.2020.89 · Cited by 53
Umetsu, R., Abe, J., Ueda, N., Kato, Y., Matsui, T., Nakayama, Y., Kinosada, Y., & Nakamura, M. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00243 · Cited by 47
Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification
Carmona-Huerta, J., Castiello-de Obeso, S., Ramírez-Palomino, J., Duran-Gutiérrez, R., Cardona-Muller, D., Grover-Paez, F., Fernández-Dorantes, P., & Medina-Dávalos, R. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2056-0 · Cited by 46
What Is New about New Antidepressants?
Dubovsky, S. L. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000488945 · Cited by 37
Case-Population Studies in Pharmacoepidemiology
Capell�, D., Pedrós, C., Vidal, X., & Laporte, J. (2002) · Drug Safety · doi:10.2165/00002018-200225010-00002 · Cited by 35
van Hunsel, F. P. A. M., van Puijenbroek, E., van den Berg, L. D. J., & van Grootheest, K. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1865 · Cited by 32
On the Reporting of Odds Ratios and Risk Ratios
Pace, N. D., & Multani, J. K. (2018) · Nutrients · doi:10.3390/nu10101512 · Cited by 30
Citrome, L., DiBernardo, A., & Singh, J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.106 · Cited by 26
Analysis of Spontaneously Reported Adverse Events
Nakamura, M. (2016) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.15-00224-5 · Cited by 19
Towards an Explanation of Subjective Ketamine Experiences among Young Injection Drug Users
Lankenau, S. E., Sanders, B., Bloom, J. J., & Hathazi, D. (2008) · Addiction Research & Theory · doi:10.1080/16066350801983749 · Cited by 15
Rees, K. E., Chyou, T., & Nishtala, P. S. (2020) · Drug Safety · doi:10.1007/s40264-020-00928-1 · Cited by 13
Pentobarbital and ketamine suppress serum concentrations of sex hormones in the female rat
Lee, C. J., Do, B.-R., Kim, J. K., & Yoon, Y. (2000) · Journal of Anesthesia · doi:10.1007/s005400070003 · Cited by 12
Approval of esketamine for treatment-resistant depression – Authors' reply
Naudet, F., & Cristea, I. A. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30040-7 · Cited by 7
Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui
Mathews, M., Daly, E. J., Popova, V., Heerlein, K., Canuso, C., & Drevets, W. C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796020000268 · Cited by 7
Longpré-Poirier, C., Jodoin, V. D., Miron, J., & Lespérance, P. (2020) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.04.024 · Cited by 7
Esketamine clinical trials: reply to Maju et al.
Gastaldon, C., Papola, D., Ostuzzi, G., & Barbui, C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602000027x · Cited by 6
Self-citationAluisio, L. E., Yieh, L., Wajs, E., DiBernardo, A., Krystal, A. D., Drevets, W. C., Wu, Y., Gogate, J. P., Daly, E., Zannikos, P., et al. (2020) · CNS Spectrums · doi:10.1017/s1092852920000589 · Cited by 5
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Ceban, F., Rosenblat, J. D., Kratiuk, K., Lee, Y. L., Rodrigues, N. B., Gill, H., Subramaniapillai, M., Nasri, F., Lui, L. M. W., Lipsitz, O., et al. (2021) · CNS Drugs · doi:10.1007/s40263-021-00846-5 · Cited by 102
Kantrowitz, J. T., Dong, Z., Milak, M. S., Rashid, R., Kegeles, L. S., Javitt, D. C., Lieberman, J. A., & John Mann, J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01541-1 · Cited by 100
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Shu, Y., Ding, Y., He, X., Liu, Y., Wu, P., & Zhang, Q. (2022) · Cancer Medicine · doi:10.1002/cam4.5062 · Cited by 85
Metadata
- Authors
- Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G.
- Affiliations
- University of Verona (IT)
- University of Bologna (IT)
- Northwell Health (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2020-08-27
- Volume
- 90
- Issue
- 1
- Pages
- 41-48
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W3082360571
- Cited by
- 134
- References
- 54
- Citations by year
- 2026: 18 · 2025: 26 · 2024: 25 · 2023: 22 · 2022: 25 · 2021: 16 · 2020: 2
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- esketamine, treatment-resistant depression, post-marketing safety, adverse event signals, dissociation, sedation, suicidal ideation, suicide mortality, venlafaxine, mood stabilizers, FDA Adverse Event Reporting System, reporting odds ratio, information component, serious adverse events, sex differences in adverse events
- MeSH terms
- Female, Humans, Ketamine, Prospective Studies, Adverse Drug Reaction Reporting Systems, Marketing, Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.